Rapigen Inc. is proud to announce that its BIOCREDIT Dengue NS1 Ag + Ab Duo Rapid Diagnostic Test has been officially listed as a Category 2 product by the World Health Organization (WHO) Expert Review Panel for Diagnostics (ERPD). This important designation affirms that the product meets WHO’s rigorous standards for safety, performance, and quality, making it eligible for international procurement and use in global public health initiatives.
In a parallel achievement, both our Dengue NS1 Ag and Dengue IgM/IgG rapid diagnostic tests received regulatory approval from ANVISA (Brazil’s National Health Surveillance Agency) in April 2025, allowing distribution and clinical use throughout Brazil.
These dual recognitions further validate the quality of Rapigen’s dengue diagnostic solutions and reinforce the company’s mission to support infectious disease control efforts through accessible, accurate, and rapid testing technologies.
Product Overview
-
Product Name: BIOCREDIT Dengue NS1 Ag + Ab Duo
-
Detection: Dengue NS1 Antigen + IgM/IgG Antibodies
-
Format: Immunochromatographic Assay
-
Specimen Type: Serum, plasma, or venous whole blood
-
Tests per Kit: 10
-
Shelf Life: 24 months
-
Storage: 2 to 40°C
-
Product Code: D30RHA10
-
WHO ERPD Round: 24-NTD-003 (Dengue)
Rapigen will be exhibiting at ADLM 2025 in Chicago from July 29–31. Visit us at our booth #4951 to learn more about our full range of molecular and rapid diagnostic solutions.
For partnership inquiries, product information, or meeting requests during ADLM 2025, please contact our team at mercy@rapigen.com.
About Rapigen
Rapigen Inc. is a Korea-based biotechnology company specializing in molecular diagnostics and rapid testing solutions for infectious diseases. With a commitment to innovation and quality, Rapigen supports global health initiatives across more than 50 countries.